Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group

异环磷酰胺 医学 养生 阿霉素 外科 化疗 泌尿科 随机对照试验 内科学 胃肠病学 依托泊苷
作者
Axel Le Cesne,Ian Judson,D. Crowther,Sjoerd Rodenhuis,H.J. Keizer,Q. van Hoesel,Jean‐Yves Blay,Jürgen Frisch,M. van Glabbeke,C. Hermans,A. van Oosterom,T Türsz,Jaap Verweij
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:18 (14): 2676-2684 被引量:254
标识
DOI:10.1200/jco.2000.18.14.2676
摘要

PURPOSE: This randomized multicenter study was designed to compare the activity of a high-dose doxorubicin-containing chemotherapy regimen with a conventional standard-dose regimen in adult patients with advanced soft tissue sarcomas (ASTS). PATIENTS AND METHODS: Between 1992 and 1995, 314 patients were randomized to receive a standard-dose regimen (arm A), containing doxorubicin (50 mg/m 2 on day 1) and ifosfamide (5 g/m 2 on day 1), or an intensified regimen (arm B), combining doxorubicin (75 mg/m 2 on day 1), the same ifosfamide dose, and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; sargramostim, 250 μg/m 2 on days 3 to 16); all courses were repeated every 3 weeks. RESULTS: The median age of the 294 eligible patients was 50 years. They received a median of five chemotherapy cycles. The median dose and relative doxorubicin dose-intensity achieved were 245 mg and 97% in arm A and 360 mg and 99% in arm B, respectively. Thirty-eight percent and 23% of patients presented with leiomyosarcomas and liver metastases, respectively. Objective responses were observed in 31 (21%) of 147 assessable patients in arm A and in 31 (23.3%) of 133 in arm B (P = .65). No change was observed in 41.6% and 46.2% of patients in arm A and B, respectively. Progression-free survival (PFS) was significantly longer in the intensive arm (P = .03). The median duration of the time to progression was 19 weeks in the conventional arm and 29 weeks in the intensified arm. There was no difference in overall survival (P = .98) between the two therapeutic arms. Toxicities were manageable in both arms. A grade 3/4 neutropenia and infection occurred in 92% and 4.6% of patients in arm A, respectively, and in 90% and 16.6% in arm B, respectively. Grade 3/4 thrombocytopenia was more frequent in arm B. CONCLUSION: The use of rhGM-CSF allowed safe escalation of chemotherapy doses. Despite a 50% increase of the doxorubicin dose-intensity, the high-dose regimen failed to demonstrate any impact on survival in patients with ASTS. The low complete response rate, the high incidence of leiomyosarcomas, and liver metastases may in part explain these results. However, the lengthening of the PFS in the intensive arm, because of the quality of stable disease and inappropriate tumor evaluation policies that potentially lead to an underestimation of antitumor activity, does not definitively refute the use of a high-dose chemotherapy regimen in selected patients with ASTS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Orange的应助被和谐的雪瑶采纳,获得30
1秒前
逆流的鱼完成签到,获得积分10
2秒前
852的应助被tang采纳,获得10
2秒前
3秒前
molihuakai的应助被Benthesikyme采纳,获得10
3秒前
1st发布了新的文献求助10
3秒前
深情安青的应助被科研通管家采纳,获得10
4秒前
4秒前
Nicu发布了新的文献求助10
4秒前
Jun的应助被科研通管家采纳,获得20
4秒前
上官若男的应助被科研通管家采纳,获得10
4秒前
5秒前
CarryLJR的应助被湖工大保卫处采纳,获得10
5秒前
爆米花的应助被科研通管家采纳,获得10
5秒前
5秒前
小萌兽发布了新的文献求助50
5秒前
Orange的应助被科研通管家采纳,获得10
5秒前
ding的应助被科研通管家采纳,获得10
5秒前
syvshc的应助被nikola采纳,获得10
5秒前
CodeCraft的应助被科研通管家采纳,获得10
5秒前
5秒前
华仔的应助被科研通管家采纳,获得10
5秒前
小二郎的应助被科研通管家采纳,获得10
6秒前
Jasper的应助被科研通管家采纳,获得10
6秒前
科研通AI6.3的应助被Bai采纳,获得10
6秒前
丘比特的应助被科研通管家采纳,获得10
6秒前
情怀的应助被科研通管家采纳,获得10
6秒前
wanci的应助被科研通管家采纳,获得10
6秒前
852的应助被1111采纳,获得10
6秒前
pykw的应助被科研通管家采纳,获得10
6秒前
爆米花的应助被科研通管家采纳,获得10
6秒前
6秒前
cheesy的应助被科研通管家采纳,获得10
6秒前
DW的应助被科研通管家采纳,获得10
7秒前
7秒前
思源的应助被科研通管家采纳,获得10
7秒前
Owen的应助被科研通管家采纳,获得10
7秒前
n01W97给听雨的求助进行了留言
8秒前
马颗粒发布了新的文献求助10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593